Drugs / REOZALIMAB
REOZALIMAB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03936959 | May 2019 → Mar 2020 | — | Eli Lilly and Company | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REOZALIMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095359 ↗ |
| Known as | LY3434172 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03936959 ↗ |
| Known as | LY3434172, A PD-1 AND PD-L1 BISPECIFIC ANTIBODY | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095359 ↗ |
| Modality | Monoclonal antibody | — CHEMBL5095359 ↗ |
| Route | Intravenous | “administered intravenously (IV)” NCT03936959 ↗ |